A new long-acting fusion inhibitor is in the pipeline in China
A new fusion inhibitor, albuvirtide, is under development in Chine. It is crucial for China, where the national health program treats around 400,000 people and expects to add another 700,000 people, to have new affordable products.
Albuvirtide, a synthetic peptide works ...
